[HTML][HTML] Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients (pts) with …
KC Weisel, P Sonneveld, MV Mateos, VTM Hungria… - Blood, 2019 - Elsevier
Introduction: Daratumumab (DARA), a human, IgGκ monoclonal antibody targeting CD38, is
approved either as a single agent or in combination with anti-myeloma regimens for newly …
approved either as a single agent or in combination with anti-myeloma regimens for newly …
[HTML][HTML] Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM) …
Introduction: Daratumumab (D) is a human monoclonal antibody targeting CD38 that is
approved as a monotherapy and in combination with standard of care regimens for patients …
approved as a monotherapy and in combination with standard of care regimens for patients …
[HTML][HTML] Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year …
Background In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
[HTML][HTML] Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma …
J Lu, W Fu, W Li, J Hu, G An, Y Wang, C Fu… - … Myeloma and Leukemia, 2021 - Elsevier
Background Daratumumab plus bortezomib/dexamethasone (D-Vd) significantly improved
outcomes versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the …
outcomes versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the …
[HTML][HTML] Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of …
MV Mateos, J Estell, W Barreto, P Corradini, CK Min… - Blood, 2016 - Elsevier
Introduction: Daratumumab is a first-in-class monoclonal antibody targeting the plasma cell
antigen, CD38, that demonstrated significant activity in combination with bortezomib and …
antigen, CD38, that demonstrated significant activity in combination with bortezomib and …
[HTML][HTML] Three-year follow up of the phase 3 pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone …
Introduction: Daratumumab is a human, CD38-targeted, IgGκ monoclonal antibody with both
direct on-tumor and immunomodulatory mechanisms of action. In the phase 3 POLLUX …
direct on-tumor and immunomodulatory mechanisms of action. In the phase 3 POLLUX …
[HTML][HTML] Efficacy and updated safety analysis of a safety Run-in cohort from Griffin, a phase 2 randomized study of Daratumumab (DarA), bortezomib (V), lenalidomide …
PM Voorhees, C Rodriguez, B Reeves, N Nathwani… - Blood, 2018 - Elsevier
Abstract Background: Dara, a human IgGκ monoclonal antibody that targets CD38, is
approved as monotherapy and in combination with Vd, Rd, and pomalidomide-d for the …
approved as monotherapy and in combination with Vd, Rd, and pomalidomide-d for the …
[HTML][HTML] Four-year follow-up of the phase 3 Pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd …
Introduction: Daratumumab, a human IgGκ monoclonal antibody targeting CD38 with a
direct on-tumor and immunomodulatory mechanism of action, is approved in combination …
direct on-tumor and immunomodulatory mechanism of action, is approved in combination …
Daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) alone in transplant-ineligible patients with …
Introduction: Daratumumab (DARA) is a human IgGκ monoclonal antibody that targets CD38
with a direct on-tumor and immunomodulatory mechanism of action. DARA is approved …
with a direct on-tumor and immunomodulatory mechanism of action. DARA is approved …
[HTML][HTML] Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible …
PM Voorhees, JL Kaufman, JP Laubach, DW Sborov… - Blood, 2019 - Elsevier
Introduction: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved as
monotherapy and in combination with standard-of-care (SoC) regimens for multiple …
monotherapy and in combination with standard-of-care (SoC) regimens for multiple …